Menopausal vasomotor symptoms

There are 13 papers on menopausal vasomotor symptoms in aging research: 2 trials and 2 observational studies in people, 8 reviews.

Disease

13 papers study it39 more mention it4 findings

7 new papers in 30 daysSee all 52 papers on menopausal vasomotor symptoms

  • Human trial2
  • Humans2
  • In silico1

Interventions

3

Elinzanetant

downin humans2

2 studies
  1. Elinzanetant decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

  2. Elinzanetant decreases menopausal vasomotor symptoms in humans (moderate to severe menopausal vasomotor symptoms).

    “Elinzanetant significantly reduced VMS frequency and severity”

    Reviewmoderate to severe menopausal vasomotor symptoms26 weeksfemales

    Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?

    Med (New York, N.Y.)

More on Elinzanetant

Fezolinetant

downin humans1

1 study
  1. Fezolinetant decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

More on Fezolinetant

Paroxetine

downin humans1

1 study
  1. Paroxetine decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

More on Paroxetine

Trial sponsors

Funding

3 grants since 2019

National Institute on Aging$4.2MUniversity of Pittsburgh$83.7K

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 0Mar 2026: 4Apr 2026: 5May 2026: 1Jun 2026: 2Jul 2026: 2Aug 2026: 2Sep 2026: 3Oct 2026: 6Nov 2026: 330 papers in 12 months

See all 52 papers on menopausal vasomotor symptoms